Open-label Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2018
At a glance
- Drugs ET-190 (Primary)
- Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Eureka Therapeutics
- 29 Jan 2018 Planned initiation date changed from 15 Jan 2018 to 5 Mar 2018.
- 22 Jan 2018 According to an Eureka Therapeutics media release, first patient enrollment is expected at Duke University in the first quarter of 2018.
- 29 Nov 2017 New trial record